Wits Helen Joseph Hospital CRS 11101 // Clinical HIV Research Unit (CHRU)

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221.
N Engl J Med. 2011 Oct 20;365(16):1482-91.

Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study.
Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F; Adult AIDS Clinical Trials Group A5221 Study Team.
Clin Infect Dis. 2013 Aug; 57(4):586-593. PMCID: PMC 3619021

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group.
HIV Med. 2008 Nov;9(10):883-96

Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa.
Fenner L, Reid SE, Fox MP, Garone D, Wellington M, Prozesky H, Zwahlen M, Schomaker M, Wandeler G, Kancheya N, Boulle A, Wood R, Henostroza G, Egger M; IeDEA Southern Africa
Trop Med Int Health. 2013 Feb;18(2):194-198

Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay.
Dhana AV, Howell P, Sanne I, Spencer D.
BMJ Case Rep. 2013 Aug.

Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa.
Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, Scott L, Stevens W, Sanne I, Van Rie A
PLoS One. 2013 June 6;8(6)

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity.
Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, Heinrich N, Hoelscher M, Diacon AH; Collaborator: Sanne I, Pan African Consortium for the evaluation of Anti-tuberculosis Antibiotics.
J Clin Microbiol. 2013 June;51(6): 1894-8. PMID: 23596237

Diagnosing Xpert MTB/RIF negative TB: Impact and cost of alternative algorithms for South Africa.
Schnippel K, Meyer-Rath G, Long L, Stevens WS, Sanne I, Rosen S.
SAMJ 2013, 103(2): 101-116. PMID: 23374320

Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I, Variava E.
Trop Med Int Health. 2013 Jan;18(1):109-16. PMID: 23170876

Immune Recovery after starting ART in HIV-Infected Patients presenting and not presenting with Tuberculosis in South Africa.
Schomaker M, Egger M, Maskew M, Garone D, Prozesky H, Hoffmann CJ, et al.
JAIDS.2013;63(1):142-5. PMCID: PMC 3671097

Point-of-care Xpert® MTB/RIF for smear negative tuberculosis suspects at a primary care clinic in south Africa
Van Rie A, Page-Shipp L, Hanrahan CF, Schnippel K, Dansey H, Bassett L, Clouse K, Scott L, Stevens W and Sanne I.
Int J Tuberc Lung Dis 2013, 17(3): 368-372. PMID: 23407225

Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis.
Van Rie A, Page-Shipp L, Mellet K, Scott L, Mkhwnazi M, Jong E, Omar T, Beylis N, Stevens W, Sanne I, Menezes CN.
Eur J Clin Microbiol Infect Dis. 2013 May 10. [Epub ahead of print] PMID:23660698

Linkage to Care and Treatment for TB and HIV among People Newly Diagnosed with TB or HIV-Associated TB at a Large, Inner City South African Hospital.
Voss de Lima Y, Evans D, Page-Shipp L, Barnard A, Sanne I, Menezes CN, Van Rie A.
PLoS One 2013, 8(1): e49140. PMCID: PMC3547004

Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level.
Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, Bassett J, Stevens W, Sanne I, Van Rie A.
S Afr Med J. 2012 Sep 7;102(10):805-7. doi: 10.7196/samj.5851.PMID: 23034211

The impact and cost of scaling up GeneXpert MTB/RIF in South Africa.
Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y and Rosen S.
PLoS One 2012, 7(5): e36966. PMCID:PMC3365041

Scaling up Xpert MTB/RIF technology: the costs of laboratory vs clinic-based roll-out in South Africa.
Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, Stevens W and Rosen S.
Trop Med & Int Health. 2012 Sept; 17(9):1142-1152. PMCID: PMC 3506730

Antiretroviral therapy initiation during tuberculosis treatment and HIV – RNA and CD4 T-lymphocyte responses.
Takuva S, Westreich D, Menezes C, McNamara L, Sanne I, Page-Shipp L and Maskew M.
International Journal of Tuberculosis and Lung Disease. 2012 Oct;16(10):1358-64. PMCID:PMC 3727657

Prevalent tuberculosis and mortality among HAART initiators.
Westreich D, Fox MP, Van Rie A and Maskew M.
AIDS 2012, 26(6): 770-773. PMCID:PMC3348652